Wet age-related macular degeneration
EYPTEyePoint pharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for DURAVYU™ (vorolanib intravitreal insert) (EYP-1901) in Wet age-related macular degeneration . The expected timing is based on the latest available company guidance and may change.
DAVIO 2, LUGANO, LUCIA trials. 10/24/24- First patient dosed in LUGANO trial. 12/4/24- First patient dosed in LUCIA trial. 8/6/25- Enrollment for both trials completed. LUCIA topline data in H2 2026. 11/19/25– IDSMC positive safety recommendation. LUGANO topline data in mid-2026. 11/05/25:- Enrollment completion and Ph3 LUGANO and LUCIA trial designs reiterated, with LUGANO topline data expected in mid-2026 and LUCIA data to follow shortly thereafter. 03/04/26:- Second DSMC review supported continuing LUGANO/LUCIA Ph3 wet AMD trials; topline data remains expected beginning mid-2026. 05/06/26:- LUGANO/LUCIA Phase 3 wet AMD trials on track; topline data beginning Mid-2026; interim safety remains favorable. 05/14/26:- Third DSMC review positive; LUGANO topline mid-2026, LUCIA shortly after. 07/30/26:- Wet AMD topline data expected beginning August 2026; May 2026 DSMC recommended continuation. 08/05/26:- LUGANO topline expected August 2026. LUCIA expected Q4 2026. Retina Society presentation planned September 2026. 08/17/26:- LUGANO topline reported. LUCIA topline expected Q4 2026; NDA filing planned H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.